"Efesovir" (FS-1) for COVID-19, Phase 2
"Efesovir" (FS-1) for COVID-19, Phase 2
Not yet recruiting · NCT05060705 · Registry updated 2024-04-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| "Efesovir" (FS-1) for COVID-19, Phase 2 | COVID-19, Coronaviridae Infections, Infections, Nidovirales infectious disease, Orthocoronavirinae infectious disease, RNA Virus Infections, lung disorder, pneumonia, respiratory system disorder, respiratory tract infectious disorder, viral infectious disease, viral pneumonia | Not yet recruiting | Phase 2 | 2024-04-17 | NCT05060705 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Scientific Center for Anti-infectious Drugs, Kazakhstan | 1 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Semey Medical University | Semey | Kazakhstan | 1 |